NEXGEL announced $1.797 million financing for a potential acquisition, pending due diligence, expected in Q1 2026.
Quiver AI Summary
NEXGEL, Inc., a provider of hydrogel products for healthcare and consumer uses, announced a financing of $1.797 million aimed at a potential acquisition set for the first quarter of 2026, pending due diligence completion by both the company and the investor. If the deal does not proceed, the funds will be returned to the investor. CEO Adam Levy emphasized NEXGEL's ongoing strategy of pursuing accretive acquisitions, noting a possible additional investment of $14.869 million contingent on successful due diligence. Further details regarding the acquisition will be shared with shareholders in early 2026. The placement agent for this transaction was Palladium Capital Group, LLC.
Potential Positives
- NEXGEL announced a financing of $1.797 million for a potential acquisition, indicating ongoing growth and strategic expansion plans.
- The potential additional investment of $14.869 million related to the acquisition signifies strong investor confidence and the company's capacity for significant growth.
- The CEO's statement highlights NEXGEL's successful track record with prior acquisitions, reinforcing the company's operational competence and strategic direction.
- Shareholders will receive further information about the acquisition in Q1 2026, demonstrating transparency and a commitment to keeping investors informed.
Potential Negatives
- The announcement of a potential acquisition, while seeking investor funds, may indicate a lack of sufficient internal resources or capital to pursue growth independently.
- The requirement for due diligence completion and the provision for returning funds if the transaction is not completed could signal uncertainty about the viability of the acquisition.
- Emphasis on "forward-looking statements" suggests that there are inherent risks associated with the acquisition, which may concern investors regarding future performance and profitability.
FAQ
What is NEXGEL's recent financing announcement?
NEXGEL announced a financing of $1.797 million related to a potential acquisition planned for Q1 2026.
Who is managing the financing transaction for NEXGEL?
Palladium Capital Group, LLC acted as the placement agent for the financing transaction.
What are NEXGEL's primary products?
NEXGEL provides healthcare, beauty, and OTC products, specializing in high-water-content hydrogel products.
What is the potential acquisition related to?
The potential acquisition involves identified assets requiring due diligence, with a total potential investment of $16.666 million.
When can shareholders expect more information on the acquisition?
Shareholders can expect further information during the first quarter of 2026 regarding the acquisition.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NXGL Insider Trading Activity
$NXGL insiders have traded $NXGL stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $NXGL stock by insiders over the last 6 months:
- ADAM R. LEVY (Chief Executive Officer) has made 0 purchases and 6 sales selling 22,000 shares for an estimated $46,047.
- SCOTT ROBERT HENRY has made 0 purchases and 3 sales selling 15,697 shares for an estimated $38,508.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NXGL Revenue
$NXGL had revenues of $2.9M in Q3 2025. This is a decrease of -0.2% from the same period in the prior year.
You can track NXGL financials on Quiver Quantitative's NXGL stock page.
$NXGL Hedge Fund Activity
We have seen 9 institutional investors add shares of $NXGL stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVERNEST FINANCIAL ADVISORS, LLC removed 281,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $685,640
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 43,626 shares (+inf%) to their portfolio in Q3 2025, for an estimated $106,447
- MORGAN STANLEY removed 34,450 shares (-28.3%) from their portfolio in Q3 2025, for an estimated $84,058
- CITADEL ADVISORS LLC added 27,454 shares (+inf%) to their portfolio in Q3 2025, for an estimated $66,987
- MALAGA COVE CAPITAL, LLC added 13,400 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,574
- DIMENSIONAL FUND ADVISORS LP added 10,541 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,720
- RENAISSANCE TECHNOLOGIES LLC added 8,621 shares (+15.7%) to their portfolio in Q3 2025, for an estimated $21,035
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL and the investor. The funds will be returned to the investor should the transaction not be consummated.
“After successfully closing and integrating several acquisitions over the last several years, we have continued to evaluate other potential accretive transactions,” said Adam Levy, CEO of NEXGEL. “We have identified assets to acquire with an up-front commitment from an investor in the amount of $1.797 million and a potential additional investment of $14.869 million relating to the acquisition, pending the completion of full due diligence by both parties and subject to other conditions. We expect to provide shareholders with further information on the acquisition during the first quarter of 2026.”
Palladium Capital Group, LLC acted as the placement agent on the transaction.
The financing transaction is more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2026.
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal
®
, Hexagels
®
, Turfguard
®
, Kenkoderm
®
and Silly George
®
. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at
http://www.sec.gov/
.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
[email protected]